Vitamin D and Hydroxyurea in Leukaemia Treatment
Author Information
Author(s): M Makishima, J Okabe-Kado, Y Honma
Primary Institution: Saitama Cancer Center Research Institute
Hypothesis
Can the combination of 1,25-dihydroxyvitamin D3 and hydroxyurea enhance differentiation and inhibit growth in human monoblastic leukaemia cells?
Conclusion
The combination of 1,25-dihydroxyvitamin D3 and hydroxyurea significantly enhances growth inhibition and differentiation in human monoblastic leukaemia cells.
Supporting Evidence
- Hydroxyurea showed the greatest synergistic effects with 1,25(OH)2D3 for growth inhibition and differentiation induction.
- Combination of 1,25(OH)2D3 with hydroxyurea significantly increased NBT-reducing activity.
- 1,25(OH)2D3 alone did not induce NBT-reducing activity in U937 cells without hydroxyurea.
Takeaway
This study found that using vitamin D with another drug can help treat a type of blood cancer by stopping the cancer cells from growing and helping them become normal cells.
Methodology
The study examined the effects of various anti-cancer drugs in combination with 1,25-dihydroxyvitamin D3 on the growth and differentiation of human monoblastic leukaemia U937 cells.
Limitations
The clinical use of 1,25-dihydroxyvitamin D3 is limited due to its hypercalcaemic activity.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.0005
Want to read the original?
Access the complete publication on the publisher's website